AAminove
Back to library

Tesamorelin

Human RCTApproved medicineWADA prohibited

Also known as: Egrifta

Growth-hormone secretagoguesHIV-associated lipodystrophy (approved)

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

A GHRH analogue approved to reduce excess abdominal fat in HIV-associated lipodystrophy. Off-label physique use is not supported by that approval.

Mechanism

Stimulates endogenous growth-hormone release; reduces visceral adipose tissue in the approved population.

Evidence

Human RCTWhat does this mean?

Strong within its approved indication; extrapolation to healthy physique use is unproven.

Community-reported information

Prescription medicine dosed per label and clinician within its indication.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

~26–38 minutes.

Storage

Refrigerate per label.

Commonly reported side effects

  • Arthralgia
  • Injection-site reactions
  • Peripheral oedema

Legal status by region

  • USFDA-approved for a specific indication; prescription only.

Legal status changes over time; verify locally before relying on this.

Citations